The case for taking account of metabolism when testing for potential endocrine disruptors in vitro

Alternatives to Laboratory Animals

Volumn 32, Issue 2, 2004, Pages 121-135

  Combes, Robert D ^a  

^a RUSSELL AND BURCH HOUSE   (United Kingdom)

Author keywords

Endocrine disruptor screening; Endogenous steroids; In vitro testing; Metabolism

Indexed keywords

16 HYDROXYESTRONE; 17 HYDROXYPREGNENOLONE; 2 HYDROXYESTRONE; 2 NITROFLUORENE; 4 HYDROXYESTRONE; 4,4' ISOPROPYLIDENEDIPHENOL; ANDROGEN; ANDROSTANE DERIVATIVE; ANDROSTENEDIONE; BENZO[A]PYRENE; BISPHENOL B; CHOLESTEROL; DEXAMETHASONE; ENDOCRINE DISRUPTOR; ENZYME; ESTRADIOL; ESTRIOL; ESTRONE; HORMONE; HYDROXYPROGESTERONE; METHOXYCHLOR; PREGNENOLONE; PROGESTERONE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; STEROID; STYRENE; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; CONTROLLED STUDY; DETOXIFICATION; DIAGNOSTIC ERROR; DRUG METABOLISM; EUROPEAN UNION; FEASIBILITY STUDY; GENETIC ENGINEERING; GENOTOXICITY; HORMONE STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; JAPAN; LAW; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; REGISTRATION; REVIEW; RISK ASSESSMENT; STEROID METABOLISM; TOXICITY TESTING; UNITED STATES;

ANIMALIA; MAMMALIA;

EID: 3242877906     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290403200210     Document Type: Review

References (84)

1. Neubert, D. (1997). Vulnerability of the endocrine system to xenobiotic influence. Regulatory Toxicology and Pharmacology 26, 9-29.
2. Baker, V. (2001). Endocrine disruptors: testing strategies to assess human hazard. Toxicology in Vitro 14, 413-419.
3. Eertmans, F., Dhooge, W., Stuyvaert, S. & Comhaire, F. (2003). Endocrine disruptors: effects on male fertility and screening tools for their assessment. Toxicology in Vitro 17, 515-524.
4. Atterwill, C. & Flack, J.D., eds (1992). Endocrine Toxicology, 475pp. Cambridge, UK: Cambridge University Press.
5. Harvey, P.W., Rush, K.C. & Cockburn, A., eds (1999). Endocrine and Hormonal Toxicology, 568pp. Chichester, UK: John Wiley & Sons.
6. Warner, M., Nilsson, S. & Gustafsson, J-Å. (1999). The estrogen receptor family. Current Opinion in Obstetrics and Gynecology 11, 249-254.
7. Weigel, N. (1996). Steroid hormone receptors and their regulation by phosphorylation. Biochemical Journal 319, 657-667.
8. Jacobs, M. (2001). Unsafe sex: how endocrine disruptors work. Pesticide Action Briefing Paper 4, January. Website http://www.pan-uk.org (Accessed 14.5.04).
9. Combes, R.D. (2000). Endocrine disruptors: a critical review of in vitro and in vivo testing strategies for assessing their toxic hazard to humans. ATLA 28, 81-118.
10. Steimer, T. (2003). Steroid Hormone Metabolism. Geneva, Switzerland: Geneva Foundation for Medical Education and Research. Website http://www.gfmer.ch/ (Accessed 14.5.04).
11. Zacharewski, T.R., Berhane, K., Gillesby, B.E. & Burnison, B.K. (1995). Detection of estrogen- and dioxin-like activity in pulp and paper mill black liquor and effluent using in vitro recombinant receptor/reporter gene assays. Environmental Science Technology 29, 2140-2146.
12. Combes, R.D. (2000). The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens. Toxicology in Vitro 14, 387-399.
13. Anon. (2001). Endocrine Disruptor Screening Program. Washington, DC, USA: US Environmental Protection Agency. Website http://www.epa.gov/scipoly/ oscpendo/index.html (Accessed 14.5.04).
14. Anon. (2001). Communication from the Commission to the Council and the European Parliament on the Implementation of the Community Strategy for Endocrine Disruptors - A Range of Substances Suspected of Interfering with the Hormone Systems of Humans and Wildlife (COM(1999) 706), COM(2001) 262 final, 45pp. Brussels, Belgium: Commission of the European Communities.
15. Dandrea, J. & Combes, R.D. (2003). A survey of stakeholder organisations on the proposed new European chemicals policy. ATLA 31, 501-528.
16. Combes, R.D. & Balls, M. (2003). How much flexibility is possible when validating new in vivo and in vitro toxicity test methods. ATLA 31, 225-232.
17. ECETOC (1996). ECETOC Document No. 33: Environmental Oestrogens: A Compendium of Test Methods, 27pp. Brussels, Belgium: European Centre for Ecotoxicology and Toxicology of Chemicals.
18. Reel, J.R., Lamb, J.C., 4th & Neal, B.H. (1996). Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundamental and Applied Toxicology 34, 288-305.
19. Holmes, P., Humfrey, C. & Scullion, M. (1998). Appraisal of test methods for sex-hormone disrupting chemicals capable of affecting the reproductive process. Document prepared by the Medical Research Council's Institute for Environment and Health, 320pp. Paris, France: OECD. Website http://www.oecd.org/ (Accessed 14.5.04).
20. 3H]oestradiol binding constants for hER-HBD. Biotechniques 18, 146-151.
21. Freyberger, A. & Scholz, G. (2004). Endocrine toxicology - contributions of in vitro methods to the 3R concept. ALTEX 21, 20-27.
22. Gray, L.E. Jr, Kelce, W.R., Wiese, T., Tyl, R., Gaido, K., Cook, J., Klinefelter, G., Desaulniers, D., Wilson, E., Zacharewski, T., Waller, C., Foster, P., Laskey, J., Reel, J., Giesy, J., Laws, S., McLachlan, J., Breslin, W., Cooper, R., Di Giulio, R., Johnson, R., Purdy, R., Mihaich, E., Safe, S., Sonnenschein, C., Welshons, W., Miller, R., McMaster, S. & Colborn, T. (1997). Endocrine screening methods workshop report: detection of estrogenic and androgenic hormonal and antihormonal activity for chemicals that act via receptor or steroidogenic enzyme mechanisms. Reproductive Toxicology 11, 719-750.
23. Balaguer, P., Joyeux, A., Denison, M.S., Vincent, R., Gillesby, B.E. & Zacharewski, T. (1996). Assessing the estrogenic and dioxin-like activities of chemicals and complex mixtures using in vitro recombinant receptor-reporter gene assays. Canadian Journal of Physiology and Pharmacology 74, 216-222.
24. Joyeux, A., Balaguer, P., Germain, P., Boussioux, A.M., Pons, M. & Nicolas, J.C. (1997). Engineered cell lines as a tool for monitoring biological activity of hormone analogs. Analytical Biochemistry 249, 119-130.
25. Ashby, J. (2000). Validation of in vitro and in vivo methods for assessing endocrine disrupting chemicals. Toxicologic Pathology 28, 432-437.
26. Purchase, I.F. (1999). Ethical review of regulatory toxicology guidelines involving experiments on animals: the example of endocrine disruptors. Toxicological Sciences 52, 141-147.
27. Lewis, D.F.V. (1996). Cytochromes P450, Structure, Function and Mechanism, 348pp. London, UK: Taylor & Francis.
28. Clarke, S.E. (1998). In vitro assessment of human cytochrome P450. Xenobiotica 28, 1167-1202.
29. Soucek, P. (1999). Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Archives of Biochemistry and Biophysics 370, 190-200.
30. Masimirembwa, C.M., Otter, C., Berg, M., Jonsson, M., Leidvik, B., Jonsson, E., Johansson, T., Backman, A., Edlund, A. & Andersson, T.B. (1999). Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metabolism and Disposition 27, 1117-1122.
31. Ozawa, S., Ohta, K., Miyajima, A., Kurebayashi, H., Sunouchi, M., Shimizu, M., Murayama, N., Matsumoto, Y., Fukuoka, M. & Ohno, Y. (2000). Metabolic activation of o-phenylphenol to a major cytotoxic metabolite, phenylhydroquinone: role of human CYP1A2 and rat CYP2C11/CYP2E1. Xenobiotica 30, 1005-1017.
32. Tanaka, E., Terada, M. & Misawa, S. (2000). Cytochrome P450 2E1: its clinical and toxicological role. Journal of Clinical Pharmacy and Therapeutics 25, 165-175.
33. Riley, R.J., Parker, A.J., Trigg, S. & Manners, C.N. (2001). Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharmaceutical Research 18, 652-655.
34. Sheweita, S.A. (2001). Drug-metabolizing enzymes: mechanisms and functions. Current Drug Metabolism 1, 107-132.
35. Combes, R.D. (1992). The in vivo relevance of in vitro genotoxicity assays incorporating enzyme activation systems. In Progress in Drug Metabolism, Vol. 13 (ed. G.G. Gibson), pp. 295-321. London, UK: Taylor & Francis.
36. Burchell, B., Soars, M., Monaghan, G., Cassidy, A., Smith, D. & Ethell, B. (2000). Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicology Letters 112-113, 333-340.
37. Glatt, H. (2000). Sulfotransferases in the bioactivation of xenobiotics. Chemico-Biological Interactions 129, 141-170.
38. MacGregor, J.T., Collins, J.M., Sugiyama, Y., Tyson, C.A., Dean, J., Smith, L., Andersen, M., Curren, R.D., Houston, J.B., Kadlubar, F.F., Kedderis, G.L., Krishnan, D., Li, A.P., Parchment, R.E., Thummel, K., Tomaszewski, J.E., Ulrich, R., Vickers, A.E.M. & Wrighton, S.A. (2001). In vitro human tissue models in risk assessment: report of a consensus-building workshop. Toxicological Sciences 59, 17-36.
39. Eling, T.E., Thompson, D.C., Foureman, G.L., Curtis, J.F. & Hughes, M.F. (1990). Prostaglandin synthase and xenobiotic oxidation. Annual Review of Pharmacology and Toxicology 30, 1-45.
40. Boyd, J.A. & Eling, T.E. (1987). Prostaglandin H synthase-catalyzed metabolism and DNA binding of 2-naphthylamine. Cancer Research 47, 4007-4014.
41. Flammang, T.J., Yamazoe, Y., Benson, R.W., Roberts, D.W., Potter, D.W., Chu, D.Z.J., Lang, N.P. & Kadlubar, F. (1989). Arachidonic acid-dependent peroxidative activation of carcinogenic arylamines by extrahepatic human tissue microsomes. Cancer Research 49, 1977-1982.
42. Doehmer, J., Krebsfänger, N., Schober, W., Luch, A., Buters, J.T.M., Jacob, J., Seidel, A., Mürdter, T., Zanger, U.M. & Eichelbaum, M. (2000). Building a biotechnology platform for metabolism studies in pharmacology and toxicology. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. M. Balls, A-M. van Zeller & M.E. Halder), pp. 139-146. Amsterdam, The Netherlands: Elsevier Science B.V.
43. Macá, K., Offord, E.A. & Pfeifer, A.M.A. (1997). Drug metabolism and carcinogen activation studies with human genetically engineered cells. In In Vitro Methods in Pharmaceutical Research (ed. J.V. Castell & M.J. Gómez-Lechón), pp. 433-456. London, UK: Academic Press.
44. Coecke, S., Catalini, P., Bull, S., Langezaal, I., Bogni, A., Bremer, S. & Balls, M. (2000). The integrated use of a genetically engineered cell line panel harbouring drug metabolizing enzymes to detect metabolism-related problem compounds. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. M. Balls, A-M. van Zeller & M.E. Halder), pp. 147-157. Amsterdam, The Netherlands: Elsevier Science B.V.
45. Bernauer, U., Glatt, H., Heinrich-Hirsh, B., Liu, Y., Muckel, E., Vieth, B. & Gundert-Remy, U. (2003). Heterologous expression of mouse cytochrome P450 2el in V79 cells: construction and characterisation of the cell line and comparison with V79 cell lines stably expressing rat P450 2E1 and human P450 2E1. ATLA 31, 21-30.
46. Gómez-Lechón, M.J., Donato, T., Ponsoda, X. & Castell, J.V. (2003). Human hepatic cell cultures: in vitro and in vivo drug metabolism. ATLA 31, 257-266.
47. Safe, S., Connor, K., Ramamorthy, K., Gaido, K. & Maness, S. (1997). Human exposure to endocrine-active chemicals: hazard assessment problems. Regulatory Toxicology and Pharmacology 26, 52-58.
48. Anon. (2002). Estrogen Receptor Binding; Estrogen Receptor Transcriptional Activation; Androgen Receptor Binding; Androgen Receptor Transcriptional Activation. ICCVAM background review documents: NIH Publication Nos 03-4504, 03-4505, 03-4506, 03-4507. Triangle Park, NC, USA: NIEHS. Website http://iccvam.niehs.nih.gov/docs/docs.htm#endocrine (Accessed 14.5.04).
49. Combes, R.D. (2003). A critical assessment of the OECD collaborative study to validate the uterotrophic assay for the detection of oestrogenic and anti-oestrogenic chemicals. ATLA 31, 489-499.
50. Lord, R.S., Bongiovanni, B. & Bralley, J.A. (2002). Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Alternative Medicine Review 7, 112-129.
51. Shou, M., Korzekwa, K.R., Brooks, E.N., Krausz, K.W., Gonzalez, F.J. & Gelboin, H.V. (1997). Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18, 207-214.
52. Dehal, S.S. & Kupfer, D. (1999). Cytochrome 3A and 2D6 catalyze ortho-hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene): involvement of catechols in covalent binding to hepatic proteins. Drug Metabolism and Disposition 27, 681-688.
53. Kronbach, T., Larabee, T.M. & Johnson, E.F. (1989). Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4. Proceedings of the National Academy of Sciences USA 86, 8262-8265.
54. Hatagima, A. (2002). Genetic polymorphisms and metabolism of endocrine disruptors in cancer susceptibility. Cadernos de Saude Publica 18, 357-377.
55. Stresser, D. & Kupfer, D. (1997). Catalytic characteristics of CYP3A4: requirement for phenolic function in ortho hydroxylation of estradiol and O-demethylated methoxychlor. Biochemistry 36, 2203-2210.
56. Safe, S. (2000). Endocrine disruptors and human health - is there a problem? An update. Environmental Health Perspectives 108, 487-493.
57. Hotchkiss, S.A.M. (1992). Skin as a xenobiotic metabolizing organ. In Progress in Drug Metabolism, Vol. 13 (ed. G.G. Gibson), pp. 217-262. London, UK: Taylor & Francis.
58. Penning, T.M. (1997). Molecular endocrinology of hydroxysteroid dehydrogenases. Endocrine Reviews 18, 281-305.
59. Honkakoski, P. & Negishi, M. (2000). Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochemical Journal 347, 321-337.
60. Campbell, M. (1994). Screening for endocrine disruption. Pesticides News 24, 8-9. Website http://www.pan-uk.org/pestnews/pn24/pn24p8.htm (Accessed 14.5.04).
61. Zacharewski, T. (1998). Identification and assessment of endocrine disruptors: limitations of in vivo and in vitro assays. Environmental Health Perspectives 106, Suppl. 2, 577-582.
62. Shelby, M.D., Newbold, R.R., Tully, D.B., Chae, K. & Davis, V.L. (1996). Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. Environmental Health Perspectives 104, 1296-1300.
63. Cassidy, A. & Milligan, S. (1998). How significant are environmental oestrogens to women? Climacteric 1, 229-242.
64. Dehal, S.S. & Kupfer, D. (1997). CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Research 57, 3402-3406.
65. Amrani, Y., Lazaar, A.L. & Panettieri, R.A. Jr (1999). Up-regulation of ICAM-1 by cytokines in human tracheal smooth muscle cells involves an NF-kappa B-dependent signaling pathway that is only partially sensitive to dexamethasone. Journal of Immunology 163, 2128-2134.
66. Vakharia, D. & Gierthy, J. (1999). Rapid assay for oestrogen receptor binding to PCB metabolites. Toxicology in Vitro 13, 275-282.
67. Yoshihara, S., Makishima, M., Suzuki, N. & Ohta, S. (2001). Metabolic activation of bisphenol A by rat liver S9 fraction. Toxicological Sciences 62, 221-227.
68. Hashimoto, Y., Moriguchi, Y., Oshima, H., Kawaguchi, M., Miyazaki, K. & Nakamura, M. (2001). Measurement of estrogenic activity of chemicals for the development of new dental polymers. Toxicology in Vitro 155, 421-425.
69. Kitamura, S., Ohmegi, M., Sanoh, S., Sugihara, K., Yoshihara, S., Fujimoto, N. & Ohta, S. (2003). Estrogenic activity of styrene oligomers after metabolic activation by rat liver microsomes. Environmental Health Perspectives 111, 329-334.
70. Meerman, J.H.N., van Lipzig, M.M.H., ter Laak, A.M., Wamelink, M., Geerke, D., Vermeulen, N.P.E. & Jongejan, A. (2003). Formation of estrogenic metabolites from polycyclic aromatic hydrocarbons and halogenated biphenyls by cytochrome P450 activity and development of a predictive computational model for binding to the estrogen receptor. Toxicology Letters 144, S181.
71. Bradlow, H.L., Davis, D.L., Lin, G., Sepkovic, D. & Tiwari, R. (1995). Effects of pesticides on the ratio of 16α/2-hydroxyestrone: a biologic marker of breast cancer risk. Environmental Health Perspectives 103, Suppl. 7, 147-150.
72. Van Duursen, M.B., Sanderson, J.T., van der Bruggen, M., van der Linden, J. & van den Berg, M. (2003). Effects of several dioxin-like compounds on estrogen metabolism in the malignant MCF-7 and nontumorigenic MCF-10A human mammary epithelial cell lines. Toxicology and Applied Pharmacology 190, 241-250.
73. Odum, J., Lefevre, P.A., Tittensor, S., Paton, D., Routledge, E.J., Beresford, N.A., Sumpter, J.P. & Ashby, J. (1997). The rodent uterotrophic assay: critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay. Regulatory Toxicology and Pharmacology 25, 176-188.
74. Harris, C.A., Henttu, P., Parker, M.G. & Sumpter, J.P. (1997). The estrogenic activity of phthalate esters in vitro. Environmental Health Perspectives 105, 802-811.
75. 2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicology in Vitro 16, 113-121.
76. Mak, P., Dela Cruz, F. & Chen, S. (1999). A yeast screen system for aromatase inhibitors and ligands for androgen receptor: yeast cells transformed with aromatase and androgen receptor. Environmental Health Perspectives 107, 855-860.
77. Liu, J., Antaya, M., Goff, A.K., Boerboom, D., Silversides, D.W., Lussier, J.G. & Sirois, J. (2001). Molecular characterization of bovine prostaglandin G/H synthase-2 and regulation in uterine stromal cells. Biology of Reproduction 64, 983-991.
78. Li, X., Bertics, P.J. & Karavolas, H.J. (1997). Regional distribution of cytosolic and particulate 5α-dihydroprogesterone 3α- hydroxysteroid oxidoreductases in female rat brain. Journal of Steroid Biochemistry and Molecular Biology 60, 311-318.
79. Fujimoto, T., Kitamura, S., Sanoh, S., Sugihara, K., Yoshihara, S., Fujimoto, N. & Ohta, S. (2003). Estrogenic activity of an environmental pollutant, 2-nitrofluorene, after metabolic activation by rat liver microsomes. Biochemical and Biophysical Research Communications 303, 419-426.
80. Gebhardt, R., Lippert, C., Schneider, A. & Doehmer, J. (1999). Improved determination of drug metabolism by perifusion of recombinant V79 cells carrying human CYP3A4. Toxicology in Vitro 13, 639-643.
81. 14C]testosterone by human foetal and adult brain tissue. Journal of Endocrinology 74, 425-429.
82. Emons, G., Merriam, G.R., Pfeiffer, D., Loriaux, D.L., Ball, P. & Knuppen, R. (2004). Metabolism of exogenous 4- and 2-hydroxyestradiol in the human male. Abstract. Website http://www.thermolife.com/ClinicalStudies-estrox2. html (Accessed 29.6.04).
83. Atkinson, A. & Roy, D. (1995). In vitro conversion of environmental estrogenic chemical bisphenol A to DNA binding metabolite(s). Biochemical and Biophysical Research Communications 210, 424-433.
84. Sakaki, T., Akiyoshi-Shibata, M., Yabusaki, Y., Manabe, K., Murakami, H. & Ohkawa, H. (1991). Progesterone metabolism in recombinant yeast simultaneously expressing bovine cytochromes P450c17 (CYP17A1) and P450c21 (CYP21B1) and yeast NADPH-P450 oxidoreductase. Pharmacogenetics 1, 86-93.